ADCT

ADC Therapeutics SA (ADCT) stock experienced several notable events in the past six months (April 2026 - October 2026). In June 2026, the stock plunged due to safety concerns and patient deaths in a blood cancer drug trial, despite positive lymphoma data from the LOTIS-5 Phase 3 trial. In August 2026, the company reported Q2 2026 financial results with $18.6 million net product revenue, beating estimates, but the stock traded lower due to FDA concerns about the benefit-risk profile of the Zynlonta combination program (LOTIS-5) and an announced 17% global workforce reduction for $10 million in annualized cost savings. In September 2026, the company participated in the 2026 Cantor Global Healthcare Conference. In October 2026, ADC Therapeutics announced a comprehensive strategic financial restructuring and expects Q3 2026 Zynlonta net product revenues of approximately $21.0 million; the share price declined significantly to $1.27 from $3.65 a year prior.